DNB Asset Management AS Reduces Holdings in Abbott Laboratories $ABT

DNB Asset Management AS reduced its position in Abbott Laboratories (NYSE:ABT) by 6.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 464,128 shares of the healthcare product maker’s stock after selling 34,333 shares during the period. DNB Asset Management AS’s holdings in Abbott Laboratories were worth $62,165,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its stake in Abbott Laboratories by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after purchasing an additional 2,977,715 shares in the last quarter. State Street Corp grew its position in shares of Abbott Laboratories by 0.9% during the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after buying an additional 689,517 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Abbott Laboratories by 3.8% in the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after buying an additional 1,390,554 shares during the last quarter. Norges Bank acquired a new stake in Abbott Laboratories in the second quarter valued at $3,026,180,000. Finally, Massachusetts Financial Services Co. MA boosted its stake in Abbott Laboratories by 5.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after acquiring an additional 821,325 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Up 1.3%

NYSE:ABT opened at $116.21 on Friday. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $141.23. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.24. The business has a 50 day simple moving average of $117.53 and a 200 day simple moving average of $125.41. The firm has a market capitalization of $201.94 billion, a P/E ratio of 31.24, a P/E/G ratio of 1.83 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio is 67.74%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the acquisition, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Analyst/bullish research: A Seeking Alpha piece argues Abbott’s recent pullback is a buying opportunity, citing attractive profitable-growth characteristics and positioning for recovery. Abbott’s Meltdown Is Worth Buying
• Positive Sentiment: Income and steady growth pitch: The Motley Fool highlights Abbott as a steady income stock with double‑digit earnings growth and a dependable dividend, supporting longer-term total‑return appeal. Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
• Neutral Sentiment: Valuation snapshot shows mixed signals: A Yahoo Finance valuation piece notes short‑term momentum has been weak and longer‑term returns negative, leaving conflicting “fair value” signals for investors to reconcile. Assessing Abbott Laboratories (ABT) Valuation
• Neutral Sentiment: Peer comparison: Coverage comparing Abbott to Intuitive Surgical frames Abbott as the steadier, dividend‑paying medtech pick, while Intuitive may offer higher growth from procedural/robotics expansion — useful for portfolio allocation but not an immediate earnings shock. Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now?
• Neutral Sentiment: Sector noise from diagnostics peers: A large drop in Grail’s stock after trial updates is creating headline risk for diagnostics names; this may press sentiment in the broader diagnostics/medtech complex but does not directly change Abbott’s fundamentals. Grail’s Stock Dropped 50% on Friday
• Negative Sentiment: Underperformance and analyst skepticism: Multiple pieces note ABT has underperformed the Nasdaq and that some research houses have trimmed price targets and flagged execution/earnings-translation risk — pressure that can weigh on sentiment until clarity on growth drivers. Is Abbott Laboratories Stock Underperforming the Nasdaq?
• Negative Sentiment: Split analyst views driving volatility: A market narrative piece documents a wide range of recent price‑target moves (some cuts, at least one raise into the mid‑$150s), leaving investors with conflicting signals and more volatile price action. How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of recent analyst reports. Barclays cut their target price on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Raymond James Financial decreased their target price on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Daiwa Securities Group dropped their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Finally, Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.